Skip to main content
. 2017 Jul 27;8(43):73372–73386. doi: 10.18632/oncotarget.19637

Figure 4. GSK-LSD1 attenuates EGF signaling.

Figure 4

A. LDH activity in HSC-3 cells treated with different concentrations of GSK-LSD1 at 24 and 48 hours; B. EGF-induced proliferation in HSC-3 cells is inhibited by GSK-LSD1; C. GSK-LSD1 inhibits phospho-AKT, -ERK1/2 and -NF-κB-p65 in HSC-3 cells and D. quantitation of this inhibition. Statistical analyses were performed with unpaired Student’s t-tests. The significant differences are indicated with *, # or $ P-value<0.005 in respective groups.